Showing results (371-380 of 470) with videos related to
Sort By:
Pageof 47
Pharmacogenetics and Genomics|May 17, 2018
Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumabJames N Ingle, Krishna R Kalari, Donald Lawrence Wickerham, et al.Cancer Research|October 21, 2016
Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor TherapyJames N Ingle, Fang Xie, Matthew J Ellis, et al.JAMA Oncology|June 27, 2024
Tumor-Infiltrating Lymphocytes in Patients With Stage I Triple-Negative Breast Cancer Untreated With ChemotherapyVeerle C M Geurts, Sara Balduzzi, Tessa G Steenbruggen, et al.Frontiers in Oncology|February 28, 2022
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b StudySara M Tolaney, Muralidhar Beeram, J Thaddeus Beck, et al.Theranostics|August 6, 2026
CTPS1 is an unexplored vulnerability in breast and ovarian cancerXiyin Wang, Michael J Emch, Lauren A Voll, et al.Oncogene|March 6, 2021
Aurora-A kinase oncogenic signaling mediates TGF-β-induced triple-negative breast cancer plasticity and chemoresistanceMohammad Jalalirad, Tufia C Haddad, Jeffrey L Salisbury, et al.Plos One|December 1, 2017
A comprehensive analysis of breast cancer microbiota and host gene expressionKevin J Thompson, James N Ingle, Xiaojia Tang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 9, 2024
Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy OutcomesPriya Rastogi, Joyce O'Shaughnessy, Miguel Martin, et al.Nature Communications|May 21, 2026
Molecular basis of allosteric regulation and pharmaceutical targeting of protein kinase CβAnh T Q Cong, Taylor L Witter, Elizabeth S Bruinsma, et al.Journal of the National Cancer Institute|December 5, 2021
Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials MethodologyRichard M Goldberg, Richard Adams, Marc Buyse, et al.Pageof 47